OSI Pharmaceuticals : Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma

Jul 15, 2008 - OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that it has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the TORC1 and TORC2 complexes that inhibits the kinase activity associated with mTOR (mammalian target of rapamycin). The study is designed to determine the maximum tolerated dose (MTD) and to establish the recommended dose and dosing schedule for Phase II trials, and will evaluate the safety and pharmacokinetic profiles of OSI-027. Preclinical studies demonstrated that orally administered OSI-027 has the potential for anti-tumor efficacy in a broad range of human cancers that depend on the mTOR pathway for tumor growth and survival, such as ovarian, colorectal, breast, lung, prostate and brain cancers, in addition to lymphoma... OSI Pharmaceuticals' Press Release -